Hacker News new | ask | show | jobs
by _heimdall 781 days ago
> Quibbling about "died with covid" versus "died of covid" isn't a useful exercise.

It isn't quibbling when the specific topic is whether or not to treat a population with an untested vaccine (assuming the trials were skipped for at risk populations as proposed above).

In a general sense, I totally agree the "with" versus "of" debate isn't useful. But when considering giving an at risk population an untested vaccine, how is that not important? Any intervention could have downsides, and more importantly an preventative intervention for a secondary infection may not be worth the risk depending on the risk profiles.

One tricky question that would have to be answered is whether the excess deaths were related to changes in nursing home treatment and general conditions. Nursing homes were effectively locked down in many areas, reducing human contact and potentially negatively impacting care. Vaccines would have no impact there, and if the untested vaccine has negative side effects we would have only made things worse.

1 comments

Vaccine risks tend to be very quickly detectable. The phase three trial timing was driven by needing enough infections and there weren't enough.
Totally fair, by far the most common vaccine issues show up soon after injection. There is still the population challenge though. Dealing specifically with patients with multiple comorbidities and prescriptions would make it pretty tricky to recognize and then isolate the risk factors of anything that does show up.

Strokes, heart attacks, circulatory issues, etc are likely pretty common in that population and any increase there after treatment may go unnoticed as a change. If you do recognize it they'd have to stop treatments entirely as you wouldn't know whether its a risk to everyone or specific to some combination of age, comorbidities, and/or other medications.

The nursing homes were charnal houses. You would need one hell of a stroke risk to make the vaccine not worth it. The andrenovirus vector clotting was fast appearing and rare enough continuing was worth it in elderly populations.